Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint

This article was originally published in The Pink Sheet Daily

Executive Summary

Continuing in its quest for the holy grail of a novel HDL cholesterol drug, Resverlogix maintains that an upcoming Phase IIb trial will test a more appropriate, higher-risk population and study patients longer.

You may also be interested in...



Resverlogix’s Reprieve: ASSURE Results Suggest RVX-208 Works When Given With Crestor

While the ASSURE study failed overall, it turns out that a subset taking the HDL-raising drug candidate with the statin Crestor did benefit from treatment; Resverlogix is now planning to develop the combination.

Resverlogix’s Reprieve: ASSURE Results Suggest RVX-208 Works When Given With Crestor

While the ASSURE study failed overall, it turns out that a subset taking the HDL-raising drug candidate with the statin Crestor did benefit from treatment; Resverlogix is now planning to develop the combination.

In Anticipation Of Acquisition, Resverlogix Spins Out Epigenetics Platform

The publicly listed Canadian biotech is prepping for a potential takeout after Phase IIb for its lead candidate by spinning out its preclinical epigenetics platform into a new private company. If Resverlogix is acquired, the newco could potentially gain a royalty from the acquirer in exchange for access to IP.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel